Dr. Reddy's Signs Supply And Licensing Deal With PanTheryx For DiaResQ

(RTTNews) - Dr. Reddy's Laboratories (RDY), an India-based pharmaceutical company, announced Thursday a multi-country supply and licensing agreement with PanTheryx, Inc., a Colorado-based medical nutrition company.

The agreement grants Dr. Reddy's the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ, for Pediatric Infectious Diarrhea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets. Dr. Reddy's will market the product in India and Nepal under the "Reliqua" brand.

DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognized in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.

Infectious diarrhea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five.